Vitamin D supplementation in renal disease: Is calcitriol all that is needed?

References

• Albright F, Drake TG, Sulkowitch HW: Ret al. osteitis fibrosa cyctica: Report of case with discussion of metabolic aspects. John Hopkins Med J 1937;60:377–385.
   Google Scholar
• Sherrard DJ, Baylink DJ, Wergedal JE, Maloney NA: Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 1974;39:119–135.
   PubMed Web of Science ®Google Scholar
• Moe S, Drueke T, Cunningham J, Goodman W, Martin K, OlgaardK, .: Kidney Disease: Improving Global Outcomes (KDOGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–1953.
   Google Scholar
• Fraser DR, Kodicek F: Unique biosysnthesis by kidney of a biologically active vitamin D metabolite. Nature 1970;228: 764–766.
   PubMed Web of Science ®Google Scholar
• Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med 1972; 287:891–895.
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Fukagawa M: Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011;15:797–809.
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Caglar G, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic kidney renal disease using proportional reduction of phosphorus intake. Kidney Int 1972;2:147–151.
   PubMed Web of Science ®Google Scholar
• Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989;83:1494–1499.
   PubMed Web of Science ®Google Scholar
• Komaba H, Fukagawa M: FGF23-parathyroid interaction. Kidney Int 2010;77:292–298.
   PubMed Web of Science ®Google Scholar
• Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest 1993; 92:1436–1443.
   Google Scholar
• Shoji T, Shinohara K, Kimoto E, Emoto M, Tanaka H, Koyama H, . Lower risk for cardiovascukar mortality in oral 1-alpha-hydroxy vitamin D3 users in a hemodialysis population. Nephrol Dial Transplant 2004;19:179–184.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446–456.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, . Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674–684.
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, Chen ZF, Liy SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of renin-angiotensin system. J Clin Invest 2002;110:229–238.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, . Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 2010;376:1543–1551.
   PubMed Web of Science ®Google Scholar
• Thraikill KT, Chan-Hee JO, Cockrell GE, Moreau CS, Fowlkes JL. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab 2011;96:142–149.
   Google Scholar
• Anderson RL, Ternes SB, Strand KA, Rowling MJ. Vitamin D homeostasis is compromised due to increased urinary excretion of the 25-hydroxycholecalciferol-vitamin D-binding protein complex in the Zucker diabetic fatty rat. Am J Physiolo Endocrinol Metab 2010;299:E959–E967.
   Google Scholar
• Hamano T, Fujii N, Matsui I, Nakano C, Inoue K, Tomida K, . Guideline-practice gap in the management of predialysis chronic kidney disease mineralbone disorder in Japan. Ther Aphr Dial 2011;15(Suppl 1):2–8.
   Google Scholar
• Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, . The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45:949–955.
   PubMed Web of Science ®Google Scholar
• Nakano C, Hamano T, Fujii N, Matsui N, Tomida K, Mikami S, . Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012; in press, doi: 10.2215/CJN.08680811.
   Google Scholar
• Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, . Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004–1013.
   PubMed Web of Science ®Google Scholar
• Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, . Serum 25-dihydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort stusy. Am J Clin Nutr 2008;87:1631–8.
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, . Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1631–1638.
   Google Scholar
• Richrart T, Li Y, Staessen JA. Renal versus extrarenal activation of vitamin D in relation to atheroscrelosis, arterial stiffening, and hypertension. Am J Hypertens 2007;20: 1007–1015.
   Google Scholar
• Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, . 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002;87:2967–72.
   PubMed Web of Science ®Google Scholar
• KDOQI: Clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–S201.
   Google Scholar
• Kidney Disease: Improving Global outcomes: KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009:76(Suppl): S1–S130.
   Google Scholar
• Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, . Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008;23:3670–3676.
   PubMed Web of Science ®Google Scholar
• Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, . Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimention parameters. Clin J Am Soc Nephrol. 2010;5:905–911.
   PubMed Web of Science ®Google Scholar
• Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol. 2007;3: 227–32.
   Google Scholar
• Bucharles S, Barberato SH, Stinghen AEM, Gruber B, Piekala L, Dambiski AC, . Impact of cholrcalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutrition 2012;22:284–291.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, . Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 2011;80:851–60.
   PubMed Web of Science ®Google Scholar
• Melamed M, Thadhani RI. Vitamin D Therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012;7:358–365.
   PubMed Web of Science ®Google Scholar